-
1 Comment
Pro Medicus Limited is currently in a long term uptrend where the price is trading 41.4% above its 200 day moving average.
From a valuation standpoint, the stock is 70.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 77.1.
Pro Medicus Limited's total revenue rose by 7.8% to $32M since the same quarter in the previous year.
Its net income has increased by 12.4% to $14M since the same quarter in the previous year.
Finally, its free cash flow grew by 89.4% to $8M since the same quarter in the previous year.
Based on the above factors, Pro Medicus Limited gets an overall score of 5/5.
CurrencyCode | AUD |
---|---|
Exchange | AU |
Industry | Health Information Services |
Sector | Healthcare |
ISIN | AU000000PME8 |
Beta | 0.59 |
---|---|
Dividend Yield | 0.4% |
Target Price | 59.8 |
PE Ratio | 130.74 |
Market Cap | 7B |
Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PME.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024